BUENOS AIRES, August 11, 2010 InspireMD Ltd. isannouncing today the availability of a new and improved delivery system forits MGuard(TM) coronary stent system. The new delivery system, which hasalready been introduced in selected regions around the world, will now makeits launch in South America during SOLACI 2010, taking place at the HiltonHotel in Buenos Aires, Argentina, August 11th-13th.
The new delivery system offers a state-of-the-art design and superiordeliverability. "We are very pleased with the flexibility and performance ofthe new delivery system. In our testing we have experienced a 15% improvementin crossing profile and 45% improvement in pushability resistance. Theseimprovements will directly benefit coronary patients in Latin America andthroughout the world," said Eli Bar, CTO and VP R&D of InspireMD.
Some of the unique advantages of the MGuard stent will be presentedduring the SOLACI congress:
Furthermore, results from the MAGICAL study and the iMOS registry will bedisplayed as posters
They will appear respectively at the 10:30 and 15:30 SOLACI PosterSessions, on Thursday, August 12th, on the Hilton Hotel's second floor hall.
Also on the agenda is InspireMD's on-booth SOLACI 2010 Welcome Cocktail,to be hosted in the InspireMD booth no.17 at 19:15 on August 11th.
About MGuard(TM) Coronary
MGuard(TM) presents a novel combination of a coronary stent merged withan embolic protection. The embolic protection is comprised of an ultra-thinpolymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stentprovides permanent embolic protection, without complicating deliverability.MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concepthas enjoyed an enthusiastic welcome from leading interventional cardiologistsaround the world.
InspireMD is an innovative medical device company focusing on thedevelopment and commercialization of its proprietary stent system technology,MGuard(TM). The company intends to apply its technology to develop productsused in interventional cardiology and other vascular procedures. InspireMD'smission is to utilize its proprietary technology to make its products theindustry standard for stents and to provide a superior solution to the keyclinical issues of current stenting: restenosis, embolic showers, and latethrombosis. In addition to providing embolic protection and minimizingarterial injury, this promising technology can be an effective and uniformdrug delivery mechanism with the help of the novel micron-level net for nextgeneration drug eluting stents. InspireMD intends to pursue applications ofthis technology both for bare metal and drug eluting stents in coronary,carotid and peripheral artery procedures.- Dr. Gian Battista Danzi will discuss the "New Methods to Treat Distal Embolization with the Micro-Mesh Covered Stent" at 10:30 on Wednesday, August 11th at the Pacara Hall of the Hilton Hotel. - Dr. Cleverson Zukowski will present a case of "Residual Intra-stent thrombosis after Coronary Angioplasty in a Critical Artery of a Patient with Acute Coronary Syndrome" at 10:30 on Thursday, August 12th at the Sauce Hall of the Hilton Hotel.
SOURCE Inspire MD